Literature DB >> 11815901

Prevention of venous thromboembolism in critically ill surgery patients: a cross-sectional study.

D Cook1, D Laporta, Y Skrobik, S Peters, M Sharpe, P Murphy, D Chin, M Crowther.   

Abstract

BACKGROUND: The risk for venous thromboembolism (VTE) and the risk for bleeding among critically ill surgical patients are both important in the early postoperative period.
MATERIALS AND METHODS: To record VTE prophylaxis prescribed for surgical patients in the intensive care unit (ICU) within the first postoperative week. We conducted a prospective observational cross-sectional study of Canadian university affiliated ICUs.
RESULTS: Of 29 ICU Directors approached, 28 (96.6%) participated, representing 34 ICUs and 589 ICU beds across Canada. Among 89 patients, surgical procedures were 32 abdominal (36.0%), 19 vascular (21.3%), 10 orthopedic (11.2%), 9 trauma (10.1%), 8 neurologic (9.0%), 5 thoracic (5.6%), 5 gynecologic (5.6%), and 1 for necrotizing fasciitis (1.1%). VTE prophylaxis with unfractionated heparin, low molecular weight heparin, and intermittent pneumatic compression was used in 35 of 89 (39.3%), 8 of 89 (9.0%), and 9 of 89 (10.1%) patients, respectively, whereas 8 of 89 (9.0%) patients were receiving therapeutic anticoagulation. Two methods of VTE prophylaxis were prescribed for 20 of 89 (22.5%) patients. Prophylaxis with unfractionated or low molecular weight heparin was significantly less likely to be prescribed for postoperative ICU patients requiring mechanical ventilation compared with those weaned from mechanical ventilation (odds ratio [OR] 0.36, P =.03). The use of intermittent pneumatic compression devices was significantly associated with current hemorrhage (OR 13.5, P =.02), and risk for future hemorrhage (OR 19.3, P =.001).
CONCLUSIONS: VTE prevention for surgical ICU patients within the first postoperative week appear to be individualized, and influenced by current and future risks of thrombosis and bleeding. Copyright 2002 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11815901     DOI: 10.1053/jcrc.2001.30665

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  4 in total

1.  Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.

Authors:  D Cook; Y Arabi; N Ferguson; D Heels-Ansdell; A Freitag; E McDonald; F Clarke; S Keenan; G Pagliarello; W Plaxton; M Herridge; T Karachi; S Vallance; J Cade; T Crozier; S Alves da Silva; R Costa Filho; N Brandao; I Watpool; T McArdle; G Hollinger; Y Mandourah; M Al-Hazmi; N Zytaruk; N K J Adhikari
Journal:  Intensive Care Med       Date:  2013-12       Impact factor: 17.440

2.  Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit.

Authors:  François Lauzier; John Muscedere; Eric Deland; Demetrios Jim Kutsogiannis; Michael Jacka; Diane Heels-Ansdell; Mark Crowther; Rodrigo Cartin-Ceba; Michael J Cox; Nicole Zytaruk; Denise Foster; Tasnim Sinuff; France Clarke; Patrica Thompson; Steven Hanna; Deborah Cook
Journal:  Crit Care       Date:  2014-04-25       Impact factor: 9.097

3.  Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial.

Authors:  Yaseen M Arabi; Sami Alsolamy; Abdulaziz Al-Dawood; Awad Al-Omari; Fahad Al-Hameed; Karen E A Burns; Mohammed Almaani; Hani Lababidi; Ali Al Bshabshe; Sangeeta Mehta; Abdulsalam M Al-Aithan; Yasser Mandourah; Ghaleb Almekhlafi; Simon Finfer; Sheryl Ann I Abdukahil; Lara Y Afesh; Maamoun Dbsawy; Musharaf Sadat
Journal:  Trials       Date:  2016-08-03       Impact factor: 2.279

4.  Clinically important deep vein thrombosis in the intensive care unit: a survey of intensivists.

Authors:  Deborah Cook; Maureen Meade; Gordon Guyatt; Lauren Griffith; John Granton; William Geerts; Mark Crowther
Journal:  Crit Care       Date:  2004-05-06       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.